Pharmaceutical

Novo Nordisk’s ocedurenone Phase III flop costs company $816m

NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.

Jun 28, 2024 - 04:00
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.
Read the original article

Tags:

Previous Article

US CDC recommends routine RSV vaccination for older adults

Next Article

FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The airline industry needs some disaster management lessons. Health care can help

Opinion: The airline industry needs some disaster manag...

Aug 1, 2023

STAT+: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs

STAT+: Pharmalittle: Appellate judges appear skeptical ...

May 19, 2023

STAT+: NIH confirmation hearing highlights just how divisive the agency’s portfolio has become

STAT+: NIH confirmation hearing highlights just how div...

Oct 18, 2023